Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr., Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
2.

Histological immune response patterns in sentinel lymph nodes involved by metastatic melanoma and prognostic significance.

Abbott J, Buckley M, Taylor LA, Xu G, Karakousis G, Czerniecki BJ, Gimotty PA, Zhang PJ.

J Cutan Pathol. 2018 Feb 15. doi: 10.1111/cup.13127. [Epub ahead of print]

PMID:
29446846
3.

Occult Breast Carcinoma Presenting as Scalp Metastasis.

Costa RLB, Costa-Filho RB, Rosa M, Czerniecki BJ.

Case Rep Oncol. 2017 Nov 10;10(3):992-997. doi: 10.1159/000484346. eCollection 2017 Sep-Dec.

4.

Transected thin melanoma: Implications for sentinel lymph node staging.

Herbert G, Karakousis GC, Bartlett EK, Zaheer S, Graham D, Czerniecki BJ, Fraker DL, Ariyan C, Coit DG, Brady MS.

J Surg Oncol. 2018 Mar;117(4):567-571. doi: 10.1002/jso.24930. Epub 2017 Nov 30.

PMID:
29194673
5.

The impact of preoperative magnetic resonance imaging and lumpectomy cavity shavings on re-excision rate in pure ductal carcinoma in situ-A single institution's experience.

So A, De La Cruz LM, Williams AD, Bahng J, Liao G, McDonald ES, Fisher CS, Czerniecki BJ, Sataloff D, Tchou J.

J Surg Oncol. 2018 Mar;117(4):558-566. doi: 10.1002/jso.24890. Epub 2017 Nov 11.

PMID:
29127721
6.

The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives.

Costa RLB, Soliman H, Czerniecki BJ.

Cancer Treat Rev. 2017 Dec;61:107-115. doi: 10.1016/j.ctrv.2017.10.005. Epub 2017 Oct 28. Review.

PMID:
29125981
7.

Oncoplastic Surgery: Keeping It Simple With 5 Essential Volume Displacement Techniques for Breast Conservation in a Patient With Moderate- to Large-Sized Breasts.

Chatterjee A, Dayicioglu D, Khakpour N, Czerniecki BJ.

Cancer Control. 2017 Oct-Dec;24(4):1073274817729043. doi: 10.1177/1073274817729043.

PMID:
28975837
8.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

9.

Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.

Nocera NF, Lee MC, Czerniecki BJ.

Future Oncol. 2017 Jul;13(17):1459-1462. doi: 10.2217/fon-2017-0151. Epub 2017 Aug 2. No abstract available.

PMID:
28766964
10.

Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.

Mustafa RE, DeStefano LM, Bahng J, Yoon-Flannery K, Fisher CS, Zhang PJ, Tchou J, Czerniecki BJ, De La Cruz LM.

Ann Surg Oncol. 2017 Oct;24(10):2999-3003. doi: 10.1245/s10434-017-5941-0. Epub 2017 Aug 1.

PMID:
28766212
11.

Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.

Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H.

Breast Cancer Res. 2017 Jun 30;19(1):75. doi: 10.1186/s13058-017-0870-1.

12.

Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma.

Sinnamon AJ, Neuwirth MG, Bartlett EK, Zaheer S, Etherington MS, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.

J Surg Oncol. 2017 Dec;116(7):848-855. doi: 10.1002/jso.24743. Epub 2017 Jun 26.

PMID:
28650537
13.

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ.

Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13.

PMID:
27965306
14.

Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer.

De La Cruz LM, McDonald ES, Mick R, Datta J, Nocera NF, Xu S, Fisher CS, Czerniecki BJ.

Ann Surg Oncol. 2017 Apr;24(4):1057-1063. doi: 10.1245/s10434-016-5651-z. Epub 2016 Nov 8.

PMID:
27826664
15.

Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis.

Karakousis G, Gimotty PA, Bartlett EK, Sim MS, Neuwirth MG, Fraker D, Czerniecki BJ, Faries MB.

Ann Surg Oncol. 2017 Apr;24(4):952-959. doi: 10.1245/s10434-016-5646-9. Epub 2016 Nov 2.

16.

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ.

Front Pharmacol. 2016 Oct 6;7:356. eCollection 2016. Review.

17.

Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.

Fracol M, Datta J, Lowenfeld L, Xu S, Zhang PJ, Fisher CS, Czerniecki BJ.

Ann Surg Oncol. 2017 Feb;24(2):407-417. doi: 10.1245/s10434-016-5584-6. Epub 2016 Sep 23.

PMID:
27663569
18.

Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

De La Cruz LM, Nocera NF, Czerniecki BJ.

Immunotherapy. 2016 Oct;8(10):1219-32. doi: 10.2217/imt-2016-0052. Review.

PMID:
27605070
19.

HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.

Ecker BL, Taylor L, Zhang PJ, Furth EE, Ginsberg GG, McMillan MT, Datta J, Czerniecki BJ, Roses RE.

PLoS One. 2016 Aug 25;11(8):e0161781. doi: 10.1371/journal.pone.0161781. eCollection 2016.

20.

Heterodyne frequency-domain multispectral diffuse optical tomography of breast cancer in the parallel-plane transmission geometry.

Ban HY, Schweiger M, Kavuri VC, Cochran JM, Xie L, Busch DR, Katrašnik J, Pathak S, Chung SH, Lee K, Choe R, Czerniecki BJ, Arridge SR, Yodh AG.

Med Phys. 2016 Jul;43(7):4383. doi: 10.1118/1.4953830.

21.

Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review.

De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, Tchou J, Fisher CS.

Ann Surg Oncol. 2016 Oct;23(10):3247-58. doi: 10.1245/s10434-016-5313-1. Epub 2016 Jun 29. Review.

PMID:
27357177
22.

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ.

Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017.

23.

Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.

Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, Lewis DA, DeMichele A, Czerniecki BJ.

JAMA Oncol. 2016 Feb;2(2):242-6. doi: 10.1001/jamaoncol.2015.5482.

PMID:
26719971
24.

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.

Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.

J Transl Med. 2015 Oct 24;13:335. doi: 10.1186/s12967-015-0698-3.

25.

Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.

Cintolo JA, Datta J, Xu S, Gupta M, Somasundaram R, Czerniecki BJ.

Melanoma Res. 2016 Feb;26(1):1-11. doi: 10.1097/CMR.0000000000000203.

PMID:
26451873
26.

Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, Koski GK, Czerniecki BJ.

Oncoimmunology. 2015 Apr 1;4(10):e1022301. eCollection 2015 Oct.

27.

Resident and Fellow Participation in Breast Surgery: An American College of Surgeons NSQIP Clinical Outcomes Analysis.

Chatterjee A, Pyfer B, Chen L, Czerniecki B, Tchou J, Fisher C.

J Am Coll Surg. 2015 Nov;221(5):988-94. doi: 10.1016/j.jamcollsurg.2015.08.008. Epub 2015 Aug 20.

PMID:
26372636
28.

Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer.

Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H, Malik M, Manahan E, O'Neill J, Patel M, Sebastian M, Wheeler A, Kass R.

Ann Surg Oncol. 2015 Oct;22(10):3184-90. doi: 10.1245/s10434-015-4753-3. Epub 2015 Jul 30. Review.

PMID:
26224406
29.

Early Postoperative Outcomes in Breast Conservation Surgery Versus Simple Mastectomy with Implant Reconstruction: A NSQIP Analysis of 11,645 Patients.

Pyfer B, Chatterjee A, Chen L, Nigriny J, Czerniecki B, Tchou J, Fisher C.

Ann Surg Oncol. 2016 Jan;23(1):92-8. doi: 10.1245/s10434-015-4770-2. Epub 2015 Jul 29.

PMID:
26219243
30.

Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity.

Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, Guerry D, Ming ME, Fraker DL, Czerniecki BJ, Gimotty PA, Karakousis GC.

Ann Surg Oncol. 2016 Jan;23(1):250-6. doi: 10.1245/s10434-015-4766-y. Epub 2015 Jul 28.

31.

Residents' Experience in Breast Cancer Care.

Conway RG, Bartlett EK, Hoffman RL, Czerniecki BJ, Karakousis GC, Kelz RR.

J Surg Educ. 2015 Nov-Dec;72(6):1233-9. doi: 10.1016/j.jsurg.2015.04.028. Epub 2015 Jun 26.

PMID:
26119094
32.

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ.

Front Immunol. 2015 Jun 2;6:271. doi: 10.3389/fimmu.2015.00271. eCollection 2015. Review.

33.

Early postoperative outcomes in lumpectomy versus simple mastectomy.

Chatterjee A, Pyfer B, Czerniecki B, Rosenkranz K, Tchou J, Fisher C.

J Surg Res. 2015 Sep;198(1):143-8. doi: 10.1016/j.jss.2015.01.054. Epub 2015 Feb 4.

PMID:
26070497
34.

Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.

Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA, DeMichele A, Yodh AG, Choe R.

Breast Cancer Res. 2015 May 27;17:72. doi: 10.1186/s13058-015-0578-z.

35.

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ.

Breast Cancer Res. 2015 May 23;17:71. doi: 10.1186/s13058-015-0584-1.

36.

CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.

Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ Jr, Czerniecki BJ.

Cancer Immunol Res. 2015 May;3(5):455-63. doi: 10.1158/2326-6066.CIR-14-0208. Epub 2015 Mar 19.

37.

Sentinel lymph node biopsy in breast cancer: a work in progress.

Chatterjee A, Serniak N, Czerniecki BJ.

Cancer J. 2015 Jan-Feb;21(1):7-10. doi: 10.1097/PPO.0000000000000090. Review.

38.

Optimizing dendritic cell-based approaches for cancer immunotherapy.

Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, Czerniecki BJ.

Yale J Biol Med. 2014 Dec 12;87(4):491-518. eCollection 2014 Dec. Review.

39.
40.

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.

Lam L, Czerniecki BJ, Fitzpatrick E, Xu S, Schuchter L, Xu X, Zhang H.

J Mol Biomark Diagn. 2014 Nov 14;4(3):151.

41.

A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr.

Hum Gene Ther. 2014 Aug;25(8):730-9. doi: 10.1089/hum.2014.006.

42.

Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Roses RE, Datta J, Czerniecki BJ.

Radiat Res. 2014 Aug;182(2):211-8. doi: 10.1667/RR13495.1. Epub 2014 Jul 3. Review.

43.

Optically measured microvascular blood flow contrast of malignant breast tumors.

Choe R, Putt ME, Carlile PM, Durduran T, Giammarco JM, Busch DR, Jung KW, Czerniecki BJ, Tchou J, Feldman MD, Mies C, Rosen MA, Schnall MD, DeMichele A, Yodh AG.

PLoS One. 2014 Jun 26;9(6):e99683. doi: 10.1371/journal.pone.0099683. eCollection 2014.

44.

Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy.

Bartlett EK, Gupta M, Datta J, Gimotty PA, Guerry D, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2014 Mar;21(3):1016-23. doi: 10.1245/s10434-013-3388-5. Epub 2013 Nov 21.

45.

Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine.

Lee MK 4th, Xu S, Fitzpatrick EH, Sharma A, Graves HL, Czerniecki BJ.

PLoS One. 2013 Nov 11;8(11):e74698. doi: 10.1371/journal.pone.0074698. eCollection 2013.

46.

Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.

Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, Xu X, Elder DE, Ming M, Elenitsas R, Guerry D, Kelz RR, Czerniecki BJ, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2014 Feb;21(2):643-9. doi: 10.1245/s10434-013-3313-y. Epub 2013 Oct 12.

47.

Racial disparities in the use of outpatient mastectomy.

Salasky V, Yang RL, Datta J, Graves HL, Cintolo JA, Meise C, Karakousis GC, Czerniecki BJ, Kelz RR.

J Surg Res. 2014 Jan;186(1):16-22. doi: 10.1016/j.jss.2013.07.055. Epub 2013 Aug 20.

PMID:
24054549
48.

Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.

Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang P, Czerniecki BJ.

Ann Surg Oncol. 2013 Oct;20(10):3233-9. doi: 10.1245/s10434-013-3119-y. Epub 2013 Jul 13.

PMID:
23851609
49.

Local immune response predicts survival in patients with thick (t4) melanomas.

Cintolo JA, Gimotty P, Blair A, Guerry D, Elder DE, Hammond R, Elenitsas R, Xu X, Fraker D, Schuchter LM, Czerniecki BJ, Karakousis G.

Ann Surg Oncol. 2013 Oct;20(11):3610-7. doi: 10.1245/s10434-013-3086-3. Epub 2013 Jul 10.

PMID:
23838911
50.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

Supplemental Content

Loading ...
Support Center